The Role of the Multidisciplinary Care Team in RCC
January 10th 2025Panelists discuss the multidisciplinary team’'s role in supporting patients through a renal cell carcinoma n( RCC) diagnosis, addressing informational gaps as patients process their diagnosis, offering supportive strategies and resources, and highlighting the unique challenges faced by patients with clear cell RCC compared to with those with non–-clear cell RCC.
Phase 3 CLEAR Trial: Evaluating Organ-Specific Progression Patterns
January 10th 2025Panelists discuss how the Phase phase 3 CLEAR trial evaluates organ-specific progression patterns in advanced renal cell carcinoma to better understand the efficacy of lenvatinib plus pembrolizumab compared to with sunitinib and guide subsequent treatment strategies.
Clinical Decision-making With TKI-IO Combinations for Advanced RCC
January 10th 2025Panelists discuss how clinical decision-making with TKI-IO combinations for advanced renal cell carcinoma involves evaluating factors such as efficacy, safety, patient characteristics, and the management of treatment-related toxicities to optimize patient outcomes.
Dosing Strategies in Different Targets Bispecifics
January 10th 2025Panelists note that while both teclistamab and elranatamab are weekly doses, elranatamab is a flat dose, and physicians have seen quick and positive responses to elranatamab treatment and physicians have seen…treatment and have been able to pull back patients from doses earlier to prevent an increase in adverse effects from infection.
Meet our 61-Year-Old Patient With Late-Line R/R on a BCMA-Targeting Bispecific
January 10th 2025Panelists discuss how patient 3 is a 61-year-old man with R-ISS stage III IgG-L double-hit myeloma/plasma cell leukemia and extramedullary plasmacytoma diagnosed in 2023 s/p radiation, now with a CNS relapse on elranatamab.
Elranatamab Dosing Strategies: Implications for Community Practice
January 9th 2025Panelists discuss how teclistamab administration and outcomes vary between academic and community settings, highlighting the need for standardized monitoring protocols, staff education, and communication frameworks to ensure consistent patient care and safety across different practice environments.
MajesTEC-1: Identifying the Optimal Patient Population for Teclistamab
January 9th 2025Panelists discuss how long-term follow-up data from MajesTEC-1 demonstrates teclistamab’s sustained efficacy and safety profile while identifying optimal candidates based on factors like prior therapy exposure, disease characteristics, and fitness level.
Navigating Treatment Options: Understanding Risks and Benefits
January 9th 2025Panelists discuss how to help patients weigh the risks and benefits of different treatment options for paroxysmal nocturnal hemoglobinuria (PNH), outlining tools and techniques used to ensure that patients and caregivers fully understand their choices and make informed decisions.
Treatment Decision-Making in PIK3CA-mut HR+/HER2- Breast Cancer: Key Tolerability Considerations
January 7th 2025Panelists discuss strategies for patient education and monitoring hyperglycemia with PI3K inhibitors, including pre-treatment screening, baseline assessments, early recognition of adverse events, and supportive care measures such as dietary modifications, with Ms. Harrington sharing practical approaches and helpful resources; Dr Isaacs comments on potential differences in adverse event management, particularly hyperglycemia, between inavolisib, capivasertib, and alpelisib, offering practical advice for oncologists; and Dr Kaklamani explores how the varying safety profiles of these agents may influence treatment selection and sequencing, including the potential for inavolisib to become standard of care in the first-line PIK3CA-mutant setting and how this will affect PI3K inhibitor sequencing in later treatment lines.
Third-Line Approach: 54-Year-Old Patient Treated With Tucatinib-Based Regimen
January 6th 2025Panelists discuss how a third-line approach for a 54-year-old patient treated with a tucatinib-based regimen involves careful consideration of prior treatment responses, comorbidities, and the potential benefits of combining tucatinib with capecitabine and trastuzumab to improve outcomes in HER2+ metastatic breast cancer.
Patient-Centered Approaches in EGFR-Mutated NSCLC
January 6th 2025Panelists discuss how oral and subcutaneous therapies have improved the quality of life for patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Squires sharing patient benefits from newer administration routes, and Dr Scott highlighting promising developments in EGFR-mutated NSCLC treatments, while exploring the evolving role of patient empowerment, self-management, and the multidisciplinary care team in supporting patients through home-based care and active participation in their treatment journey.
Empowering Patients in Treatment Planning
January 4th 2025Panelists discuss resources and strategies to help patients and caregivers cope with the initial shock of a paroxysmal nocturnal hemoglobinuria (PNH) diagnosis, emphasizing critical points during the first consultation, and explore how Brandi communicated her treatment preferences to her care team, reflecting on her sense of inclusion in the decision-making process and areas for improvement.
Comparative Outcomes: Talquetamab vs Physician's Choice in R/R Multiple Myeloma
January 3rd 2025Panelists discuss how talquetamab demonstrates superior efficacy compared with physician-chosen treatments for patients with heavily pretreated multiple myeloma, with improved progression-free survival and response rates.